Actively Recruiting
Medrol Dosepak for Outpatient Total Knee Arthroplasty
Led by Rush University Medical Center · Updated on 2026-04-14
420
Participants Needed
1
Research Sites
248 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the efficacy of an oral methylprednisolone taper on acute postoperative pain, function, opioid consumption, nausea, and complications following outpatient total knee arthroplasty (TKA). We hypothesize that administration of an oral methylprednisolone taper starting on postoperative day 1 (POD 1) following TKA will be associated with improved pain and decreased opioid use, nausea, and complications at POD1-7, as compared to similar patients who receive placebo. Additionally, those taking methylprednisolone will report decreased pain and greater objective functional outcomes at 3 and 6 weeks postoperatively as compared to controls.
CONDITIONS
Official Title
Medrol Dosepak for Outpatient Total Knee Arthroplasty
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Any patient undergoing primary total knee arthroplasty with a diagnosis of osteoarthritis
- 18 years old or older
- Willingness to undergo randomization
You will not qualify if you...
- Chronic corticosteroid or opioid use
- Suspected or confirmed periprosthetic joint infection
- Revision total knee arthroplasty
- Primary diagnosis other than osteoarthritis, such as avascular necrosis, fracture, or post-traumatic arthritis
- American Society of Anesthesiologists (ASA) score 4 or higher
- History of liver disease, renal disease, or diabetes mellitus
- Current systemic fungal infection or other local infection
- Immunocompromised or immunosuppressed status
- Current peptic ulcer disease
- History of hypothyroidism, psychosis, heart failure, myasthenia gravis, ocular herpes simplex virus, or systemic sclerosis
- Current pregnancy
- Known hypersensitivity to methylprednisolone
- Under 18 years old
- Inability to take oral medications
- Unable to provide consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rush Oak Brook Outpatient Center
Oak Brook, Illinois, United States, 60523
Actively Recruiting
Research Team
A
Anne DeBenedetti
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here